ContraFect_LOGO_Web.jpg
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
July 19, 2021 07:31 ET | ContraFect Corporation
YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Summit logo.png
Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole
July 12, 2021 08:29 ET | Summit Therapeutics Inc.
Cambridge, MA, July 12, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying three preeminent ePosters at the prestigious 31st European...
Summit logo.png
Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster
July 01, 2021 08:00 ET | Summit Therapeutics Inc.
Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Company”) today announced that members of our scientific team will present breakthrough research...
ContraFect_LOGO_Web.jpg
ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book
May 11, 2020 07:30 ET | ContraFect Corporation
YONKERS, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
January 27, 2020 07:00 ET | ContraFect Corporation
YONKERS, New York, Jan. 27, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Summit Master_rgb_png.png
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
April 14, 2019 07:42 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 ...
Centauri-logo.png
Centauri Therapeutics to present at 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
April 10, 2019 02:00 ET | Centauri Therapeutics Limited
Centauri Therapeutics to present at 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) UK, 10 April 2019: Centauri Therapeutics (“Centauri”), an immunotherapy...
Summit Master_rgb_png.png
Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
April 03, 2019 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae   Data to be Presented in Oral Session at...
Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
April 23, 2018 07:00 ET | Summit Therapeutics plc
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces it highlighted the discovery of new mechanism antibiotic...
MBI_Logo_Tagline_Blue.jpg
ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection
April 17, 2017 05:30 ET | Meridian Bioscience, Inc.
VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) -- Leading malaria researcher Tom van Gool’s presentation at the 27th European Congress for Clinical Microbiology and Infectious Diseases (ECCMID)...